Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 66.30M shares outstanding
No company description available.
Employees
--
Country
--
Sector
Healthcare
Website
--
Loading congressional disclosures…
based on 66.30M shares outstanding
30d Avg
434.76K
60d Avg
318.55K
90d Avg
386.87K
